Merck’s Biopharmaceutical Innovations Transforming Healthcare in Indonesia

Date:

Merck’s Biopharmaceutical Innovations Transforming Healthcare in Indonesia

The healthcare industry in Indonesia is experiencing significant expansion as the government strives to provide quality health services across the country’s vast archipelago. Despite making great strides, the COVID-19 pandemic has exposed flaws in the system, highlighting the need for continued improvement. Merck, a leading science and technology company, is at the forefront of transforming healthcare in Indonesia, with a focus on long-term partnership and a commitment to putting people above profit.

With a history spanning over 350 years, Merck has established itself as a family-owned business dedicated to making a positive impact on people’s lives. In Indonesia, the company believes that biopharmaceutical innovation is key to driving sustainable progress in the pharmaceutical sector. While the government prioritizes economic recovery, Merck emphasizes the importance of encouraging and incentivizing biopharmaceutical innovation, as an improved population health will ultimately enhance Indonesia’s competitiveness as an economy.

Hong Chow, head of China and international healthcare at Merck, expressed her motivation for driving change in the industry, stating, What motivates us is not selling more drugs but improving the health of people around the world. Merck’s approach prioritizes prevention and early diagnosis, exemplified by their disease awareness campaigns such as the RAISE Thyroid Program in Indonesia.

As a company that strives to create, improve, and prolong lives, Merck contributes to the healthcare of over 90 million patients worldwide annually. The company focuses on four core specialties: fertility, neurology and immunology, cardiometabolic and endocrinology, and oncology.

In the realm of fertility, Merck leads the market in hormone-based treatments, having supported the birth of over 5 million babies. Their unique offering includes recombinant versions of three natural hormones used for treating infertility, along with user-friendly, ready-to-use injection devices for in vitro fertilization (IVF) treatments. Merck also leverages scientific advancements and digitalization to enhance outcomes for assisted reproductive treatment (ART) patients, utilizing AI and robotics for improved embryo handling during IVF.

See also  CEOs Embrace AI for Competitive Edge as IBM Launches Watsonx Platform for Indonesian Businesses

Merck recognizes the importance of addressing chronic diseases that may not be life-threatening on their own, but can lead to severe complications and disabilities. Conditions such as diabetes, thyroid disorders, and cardiovascular diseases can significantly impact individuals’ lives. By implementing digitalization and raising awareness about thyroid disorders, Merck aims to improve the early detection and treatment of these conditions. In Indonesia, the prevalence of hypothyroidism is around 12.6 million, while hyperthyroidism affects around 13.4 million people. Unfortunately, the diagnosis and treatment rates for thyroid disorders in Indonesia are less than 2 percent, in stark contrast to developed markets like Germany, where the rates reach 70 percent.

To address this disparity, Merck has initiated the RAISE Thyroid Program, which aims to engage with approximately 52,000 healthcare professionals and extend thyroid disorder screenings to 3 million high-risk adults across 7,000 healthcare facilities in Indonesia.

Through their biopharmaceutical innovations and commitment to improving healthcare, Merck is playing a pivotal role in transforming the healthcare landscape in Indonesia. By prioritizing prevention, early diagnosis, and advancements in fertility and chronic disease treatment, the company is making a significant impact on the well-being of millions of people in the country. As the government continues its efforts to expand and enhance the healthcare system, partnerships with innovative companies like Merck will be crucial in achieving the goal of providing quality healthcare services to all Indonesians.

Frequently Asked Questions (FAQs) Related to the Above News

What is Merck's role in transforming healthcare in Indonesia?

Merck is at the forefront of transforming healthcare in Indonesia with a focus on long-term partnership and a commitment to putting people above profit. They believe that biopharmaceutical innovation is key to driving sustainable progress in the pharmaceutical sector and improving population health.

How does Merck prioritize prevention and early diagnosis?

Merck prioritizes prevention and early diagnosis through disease awareness campaigns like the RAISE Thyroid Program in Indonesia. They aim to engage healthcare professionals and extend thyroid disorder screenings to high-risk adults across thousands of healthcare facilities in the country.

What are the core specialties that Merck focuses on in healthcare?

Merck focuses on four core specialties in healthcare: fertility, neurology and immunology, cardiometabolic and endocrinology, and oncology. They specialize in hormone-based treatments, assisted reproductive treatments, chronic disease management, and cancer care.

How does Merck contribute to fertility treatments?

Merck leads the market in hormone-based treatments for fertility and has supported the birth of over 5 million babies. They offer recombinant versions of three natural hormones used for treating infertility and provide user-friendly injection devices for in vitro fertilization (IVF) treatments. Merck also utilizes scientific advancements and digitalization to enhance outcomes for assisted reproductive treatment (ART) patients.

How does Merck address chronic diseases in healthcare?

Merck recognizes the importance of addressing chronic diseases that can significantly impact individuals' lives. They implement digitalization and raise awareness about conditions such as diabetes, thyroid disorders, and cardiovascular diseases. Their focus is on improving early detection and treatment of these conditions.

What is the RAISE Thyroid Program initiated by Merck?

The RAISE Thyroid Program aims to engage with healthcare professionals and extend thyroid disorder screenings to high-risk adults in Indonesia. It is part of Merck's efforts to improve the diagnosis and treatment rates for thyroid disorders in the country, where the rates are currently less than 2%, compared to 70% in developed markets like Germany.

How is Merck making a significant impact on the healthcare landscape in Indonesia?

Through their biopharmaceutical innovations and commitment to improving healthcare, Merck is making a significant impact on the well-being of millions of people in Indonesia. By prioritizing prevention, early diagnosis, and advancements in fertility and chronic disease treatment, they are transforming the healthcare landscape and contributing to the government's goal of providing quality healthcare services to all Indonesians.

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Share post:

Subscribe

Popular

More like this
Related

Libya Launches National AI Policy on World Telecommunication Day

Libya launches National AI Policy on World Telecommunication Day to promote innovation in the digital sector and drive progress.

Google Integrates Search Engine with AI, Concerns Raised by Web Publishers

Google's integration of search engine with AI raises concerns among web publishers. Expert insights on potential impacts and challenges.

The Dark Side of AI Companions: Will Chatbots Replace Human Connection?

Discover the dark side of AI companions in tackling loneliness. Will chatbots really replace human connection? Find out now.

China’s First Sci-Fi Movie Red Earth Wraps Filming, Promises High-Tech Thrills

Red Earth, China's first sci-fi internet movie showcases cutting-edge technologies in a post-nuclear war setting, promising visually stunning futuristic depictions.